Cognito Therapeutics Showcases Early-Stage Cost-Effectiveness of Spectris Therapy for Alzheimer’s Disease
Cognito Therapeutics, a neurotechnology company focused on advancing disease-modifying therapies for CNS diseases, recently presented an early-stage cost-effectiveness analysis of its Spectris™ therapy for Alzheimer’s disease (AD) at the International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR Europe) 2024 Annual Meeting in Barcelona, Spain. The analysis underscores the potential of Spectris to offer a cost-effective, non-pharmacologic alternative to current AD treatments, which could significantly reduce the financial burden on patients and healthcare systems.
Spectris therapy utilizes non-invasive visual and auditory stimulation to evoke brain gamma band oscillations, showing promising results in slowing the progression of AD symptoms. This innovative approach not only presents a potentially disease-modifying treatment option but also aims to minimize the high costs associated with AD care. Data from Cognito’s Phase II OVERTURE study revealed that the active therapy group experienced a 77% reduction in decline in daily function compared to the sham treatment group, as measured by the Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL).
The cost-effectiveness model for Spectris therapy, based on various efficacy scenarios and a $100,000 willingness-to-pay (WTP) threshold, estimates its economic value for mild-to-moderate AD patients. The model projects an additional life year (LY) and 1.13 quality-adjusted life years (QALYs) gained with Spectris, highlighting its potential to improve patient outcomes over their lifetime. With an acquisition cost ranging from $44,000 to $108,000, Spectris is positioned as a durable, cost-effective option that could reduce annual care expenses without the significant side effects and ongoing treatment costs associated with newly approved monoclonal antibody therapies.
Dr. Ralph Kern, M.D., MHSc, Chief Medical Officer of Cognito Therapeutics, emphasized the significance of the data presented at ISPOR, stating, "Spectris aims to fill a critical unmet need in AD care, by potentially providing a safe treatment that improves patient outcomes while limiting the financial burden on patients and the healthcare system." This presentation marks a milestone for Cognito Therapeutics and the millions affected by Alzheimer’s disease, offering hope for a more accessible and effective treatment option.